A retrospective analysis of patients on semaglutide or liraglutide found that 12.7% developed at least one nutritional deficiency within six months of starting therapy
those switched to placebo regained about 14% over the next year. Weight loss slows toward a plateau on a held dose rather than continuing indefinitely
may cause iron-deficiency anemia Nausea and vomiting particularly with stricturing disease/obstruction Urgency and tenesmus with rectal/colonic involvement Weight loss and malnutrition due to malabsorption, food avoidance, elevated metabolic demand Fever with active inflammation, abscess, or fistula Perianal disease fissures, fistulae, skin tags, abscesses Extraintestinal Manifestations Arthropathy peripheral or axial (enteropathic arthritis, M07.6x) Dermatologic: Erythema nodosum (L52), pyoderma gangrenosum, psoriasis (L40.5) Ocular: Uveitis/iritis (H20.01), episcleritis, scleritis Hepatobiliary: Primary sclerosing cholangitis (K73.2), fatty liver, cholelithiasis Metabolic: Osteopenia/osteoporosis (from steroid use and malabsorption), nephrolithiasis Hematologic: Anemia (iron deficiency, B12/folate deficiency, anemia of chronic disease) When a patient with Crohns disease is admitted with significant weight loss, malnutrition, or protein-calorie deficiency , query the provider to specify the degree of malnutrition (mild, moderate, severe protein-calorie malnutrition)
Procedures are incredibly quick
&srotate=0)
